Redefining first-line standards: The role of next-generation HER2-Targeted therapies in HER2-positive metastatic breast cancer
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026-09 · 1881 (4) · 189649
DOI: 10.1016/j.bbcan.2026.189649 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026-09. Verfasst von Lanxin Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 135 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Dalian Medical University, Chinese Academy of Sciences.
Abstract (Originalsprache)
The combination of trastuzumab, pertuzumab, and taxane (THP) has been the cornerstone of the first-line treatment for human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC) since the CLEOPATRA trial. However, this long-standing paradigm is now being redefined by compelling evidence from practice-changing trials. Recent advances are challenging THP's dominance with impressive clinical activity across multiple trials evaluating anti-HER2 antibody-drug conjugates (ADC) and CDK4/6 inhibitors. The DESTINY-Breast09 (DB09) trial established superiority of the ADC trastuzumab deruxtecan (T-DXd) combined with pertuzumab over THP, positioning chemotherapy-free strategies as potential new standards. For patients with HR+/HER2+ disease, the PATINA study extends the first-line strategy by demonstrating that adding a CDK4/6 inhibitor as maintenance therapy significantly improves outcomes for patients with HR+/HER2+ disease who have completed initial THP induction. This review comprehensively summarizes the evolution of first-line treatment strategies for HER2+ mBC and critically evaluates clinical evidence from pivotal trials, including emerging evidence in first-line treatments and new agents with potential first-line applications. Challenges, including drug resistance mechanisms, optimal treatment sequencing, and management of special populations, are also discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China.
- Dalian Medical University, Dalian, Liaoning, China.
- Dalian University, Dalian, Liaoning, China. Electronic address: dlzhaozw@163.com.
- Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China. Electronic address: man_li@dmu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Dalian Medical University
- Chinese Academy of Sciences
- Dalian Institute of Chemical Physics, Chinese Academy of Sciences
- Natural Science Foundation of Liaoning Province
Zitieren
APA
Zhang, L., Li, H., Sun, S., Li, N., Zhao, S., Zhao, Z., & Li, M. (2026). Redefining first-line standards: The role of next-generation HER2-Targeted therapies in HER2-positive metastatic breast cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1881(4), 189649. https://doi.org/10.1016/j.bbcan.2026.189649
Vancouver
Zhang L, Li H, Sun S, Li N, Zhao S, Zhao Z, et al. Redefining first-line standards: The role of next-generation HER2-Targeted therapies in HER2-positive metastatic breast cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026;1881(4):189649. doi:10.1016/j.bbcan.2026.189649
BibTeX
@article{Zhang2026,
author = {Zhang, Lanxin and Li, Huazhang and Sun, Siwen and Li, Ning and Zhao, Shanshan and Zhao, Zuowei and Li, Man},
title = {Redefining first-line standards: The role of next-generation HER2-Targeted therapies in HER2-positive metastatic breast cancer},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2026},
volume = {1881},
number = {4},
pages = {189649},
doi = {10.1016/j.bbcan.2026.189649}
}
EUVIMED